Physical Treatment Patents (Class 530/427)
-
Patent number: 5102934Abstract: Organic materials which are normallly susceptible to oxidative deterioration are stabilized with tertiary sulfonamide antioxidants corresponding to the formula: ##STR1## wherein R and R' are independently selected from alkyl, aryl, and benzyl groups, R" is an alkylene group containing 1-5 carbons, and n is an integer of 1-3.Type: GrantFiled: March 15, 1991Date of Patent: April 7, 1992Assignee: Ethyl CorporationInventor: Vincent J. Gatto
-
Patent number: 5103054Abstract: Tertiary sulfonamides having utility as antioxidants are compounds corresponding to the formula: ##STR1## wherein R and R' are independently selected from alkyl, aryl, and benzyl groups, R" is an alkylene group containing 1-5 carbons, and n is an integer of 1-3.Type: GrantFiled: March 15, 1991Date of Patent: April 7, 1992Assignee: Ethyl CorporationInventor: Vincent J. Gatto
-
Patent number: 5102987Abstract: The .alpha.-chlorohydrin content of liquid hydrolysed protein obtained by acid hydrolysis with hydrochloric acid is reduced by adjusting the pH of the liquid hydrolysed protein to a pH of from 8 to 14 and holding the liquid for a time sufficient for the .alpha.-chlorohydrin content of the liquid hydrolysed protein to be reduced.Type: GrantFiled: October 14, 1988Date of Patent: April 7, 1992Assignee: Nestec S.A.Inventors: Paul E. Cornet, Rebecca S. So, John S. Tandy
-
Patent number: 5097017Abstract: Process for making soy protein concentrate which includes agglomerating either dusty defatted soybean flakes or the dust itself in a screw device with substantially no die restriction at the discharge end, the material to be agglomerated having been subjected to moisture addition to bring the moisture content to 18-30%, maintaining the temperature in the range of 160.degree.-300.degree. and thereafter extracting the agglomerated material with 55-75% aqueous ethanol.Type: GrantFiled: December 13, 1990Date of Patent: March 17, 1992Assignee: Central Soya Company, Inc.Inventor: Arthur H. Konwinski
-
Patent number: 5095092Abstract: The invention relates to a process for the isolation and purification of hirudin from complex and salt-containing solutions by hydrophobic chromatography, using as stationary phase porous adsorber resins and as mobile phase organic solvents which are miscible with water.Type: GrantFiled: September 27, 1990Date of Patent: March 10, 1992Assignee: Hoechst AktiengesellschaftInventors: Werner Badziong, Peter Crause, Paul Habermann, Dominique Tripier
-
Patent number: 5030720Abstract: Hepatitis B PreS2+S antigen is isolated from plasma by adsorption on an affinity chromatography column, elution with a chaotropic agent and treatment with concentrated urea at an elevated temperature. The process retains all or substantially all of the preS2+S antigen.Type: GrantFiled: September 1, 1988Date of Patent: July 9, 1991Assignee: Merck & Co., Inc.Inventors: Alexander U. Bertland, II, William J. Miller
-
Patent number: 5017375Abstract: The present invention is based on the discovery that amyotrophic lateral sclerosis (ALS), Parkinson disease and Alzheimer disease are due to lack of a disorder-specific neurotrophic hormone or factor. Diagnosis is accomplished by assaying factors specific for a particular neuronal network or system; for example, dopamine neutotrophic hormones from striatum or caudate-putamen in the nigrostriatal dopaminergic neural system are used to diagnose and treat parkinsonism. With tissue culture, the presence or absence of spacific neurotrophic factos can be assessed in ALS, parkinsonism, and Alzheimer disease. If there is a deficiency, extracted and purified neurotrophic factors specific to the particular neuronal network or system can be injected into a patient having ALS, Alzheimer disease or parkinsonism for treatment of the disease.Type: GrantFiled: May 18, 1987Date of Patent: May 21, 1991Assignee: Baylor College of MedicineInventors: Stanley H. Appel, Yasuko Tomozawa
-
Patent number: 5011914Abstract: A ciliary neurotrophic factor (CNTF), particularly sciatic nerve CNTF (SN-CNFT) is claimed. The SN-CNTF described herein is a single protein species and has a specific activity that increased to greater than 25,000-fold from crude extract. The purification is carried out by lowering the pH of the crude nerve extract preparation to form a precipitate which is removed and discarded; raising the pH to about 6.3 followed by ammonium sulfate fractionation; chromatofocusing a solution containing a second precipitate obtained from the 30% to 60% ammonium sulfate containing solution; subjecting the fractions obtained by chromatofocusing to sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE); and performing reversed-phase high-performance liquid chromatography (HPLC) on the SDS-PAGE eluate.Amino acid data for this SN-CNTF is also provided. In addition, methods for using this data for providing SN-CNTF probes and for screening cDNA and genomic libraries are also provided.Type: GrantFiled: January 5, 1989Date of Patent: April 30, 1991Inventors: Franklin D. Collins, Leu-Fen Lin
-
Patent number: 5006642Abstract: A method of preparing von Willebrand Factor by disassociating it from a chaotropic agent in solution therewith and preferably treating the same under controlled temperature either in liquid or lyophilized form.Type: GrantFiled: June 13, 1988Date of Patent: April 9, 1991Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.Inventors: Jack Newman, David L. Farb
-
Patent number: 5003047Abstract: A method for purifying a biologically active ligate. In this method, a ligand bonded to a first phase and having a specific affinity for the ligate is provided. The ligate is provided with a second phase. The first and second phases are then contacted together under conditions in which the ligand and ligate form a complex bonded to the first phase, with the ligand and ligate held together only by one or more non-covalent pressure sensitive bonds. At least a part of the second phase is then separated from the first phase to provide a purified first phase, and the purified first phase subjected to a pressure of at least 300 atmospheres under conditions sufficient to cause release of the ligate from the complex, but not sufficient to cause significant release of the ligand from the first phase. These conditions do not irreversibly cause biological activity of the ligate to be significantly reduced.Type: GrantFiled: January 10, 1989Date of Patent: March 26, 1991Assignee: Massachusetts Institute of TechnologyInventors: Martin L. Yarmush, William C. Olson
-
Patent number: 4999422Abstract: A process is disclosed for continuously treating a solubilized protein solution containing a protein unfolded to some degree, in a small volume continuous flow reactor, to obtain the protein in a conformation exhibiting the protein's characteristic biological activity by continuously diluting out the solubilizing agent, while continuously withdrawing the refolded protein. The continuous process may be carried out using deionized water as a diluent, rather than buffer solutions.Type: GrantFiled: April 15, 1988Date of Patent: March 12, 1991Assignee: Biogen, N.V.Inventor: Parrish M. Galliher
-
Patent number: 4997916Abstract: A method is provided for recovering a purified animal growth hormone or a polypeptide analog thereof having substantially the same amino acid sequence as, and the biological activity of, the corresponding naturally-occurring animal growth hormone from a bacterial cell in which the animal growth hormone or polypeptide analog has been produced by means of expression of a plasmid encoding the hormone or polypeptide analog which comprises: (a) disrupting the cell wall of the bacterial cell in a buffered neutral pH solution so as to produce a lysate containing precipitated hormone or polypeptide analog; (b) recovering the resulting precipitated hormone or polypeptide analog; (c) suspending the precipitated hormone or polypeptide analog so recovered in distilled water; (d) treating the resulting precipitate-containing suspension with a sodium hydroxide solution having an alkaline pH of about 11.Type: GrantFiled: March 7, 1989Date of Patent: March 5, 1991Assignee: Bio-Technology General Corp.Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel, Elisha Zeelon, Menachem Zeevi
-
Patent number: 4996194Abstract: Composition for the prevention and treatment of autoimmune diseases are provided which comprise as an active ingredient membrane material shed from autoimmune T lymphocytes, or activated T lymphocytes which are treated by a pressure application and releases process. There is also provided processes for obtaining such active materials and for preparing pharmaceutical compositions containing them.Type: GrantFiled: September 23, 1986Date of Patent: February 26, 1991Assignee: Yeda Research and Development Co. Ltd.Inventors: Irun R. Cohen, Meir Shinitzky
-
Patent number: 4975526Abstract: Disclosed is a matrix material for implantation in a mammalian host comprising biocompatible mineral-free type I bone collagen, xenogenic to the host, and biodegradable therewithin. The matrix is manufactured from protein-extracted bone powder treated with certain swelling agents to increase its surface area and porosity. The matrix may be combined with osteogenic protein to induce reliably and reproducibly endochondral bone formation. It also can be used as a surface coat around implantable prosthetic devices to promote cellular ingrowth or as a carrier for sustained release of various therapeutic compositions.Type: GrantFiled: October 17, 1989Date of Patent: December 4, 1990Assignee: Creative Biomolecules, Inc.Inventors: Thangavel Kuberasampath, Richard J. Ridge
-
Patent number: 4958007Abstract: A method is provided for extracting human interleukin-4 (IL-4) from IL-4 expressing bacterial cells. The method comprises treating the bacterial cells with a deactivating agent, disrupting the cell membrane and recovering the IL-4.Type: GrantFiled: May 17, 1988Date of Patent: September 18, 1990Assignee: Schering-Plough Corp.Inventors: Yair Alroy, Paul Leibowitz
-
Patent number: 4931275Abstract: There are provided anti-tumor vaccines which contain as active ingredient tumor cells which have been pressure treated so as to augment their antigenic properties, tumor cells treated with cholesteryl hemisuccinate (CHS) and subsequently pressure treated, or plasma membranes from either of, or membrane proteins shed from either of these cells, or a combination of any of these. According to another embodiment, tumor cells are treated with cholesteryl hemisuccinate or by the application and release of pressure, and subsequently with a cross-linking agent. Such cells, plasma membranes obtained from these and proteins shed from the surface of these are effective active ingredients in anti-tumor vaccines.Type: GrantFiled: May 24, 1988Date of Patent: June 5, 1990Assignee: Yeda Research & Development Co., Ltd.Inventors: Meir Shinitzky, Irun R. Cohen
-
Patent number: 4923967Abstract: The present invention discloses a new method for solubilizing and refolding recombinant proteins expressed as granules. The method involves sulfitolysis and the formation of a precipitate of protein-S-sulfonate by warming. The precipitate has been found to contain protein in high purity. In addition, proper folding takes place if the desired protein is fully reduced and passed through an intermediate concentration of denaturant which allows for a transition between its folded and unfolded states.Type: GrantFiled: September 26, 1988Date of Patent: May 8, 1990Assignee: Eli Lilly and CompanyInventors: Jesse L. Bobbitt, Joseph Manetta
-
Patent number: 4912200Abstract: A method of extracting granulocyte macrophage colony stimulating factor (GM-CSF) from GM-CSF-expressing bacterial cells comprising treating a suspension of GM-CSF-containing bacterial cells with an acid and an enhancing agent, removing substantially all of the suspension liquid from the cells, preparing a second suspension of the acidified cells, neutralizing said second suspension, and separating the GM-CSF containing liquid from the suspended cells.Type: GrantFiled: May 11, 1987Date of Patent: March 27, 1990Assignee: Schering CorporationInventors: Paul Leibowitz, Yair Alroy
-
Patent number: 4906616Abstract: A medicinal composition, particularly but not exclusively for use in fluids for medical dialysis, contains, as an agent for maintaining the osmolality of the fluid, a protein hydrolysate resulting from the action of a proteolytic enzyme on the sodium caseinate fraction of milk protein. The enzyme is preferably trypsin but other proteolytic enzymes and enzyme mixtures may be used, examples being chymotrypsin, pancreatin and pronase.The method of production involves treating the sodium caseinate in aqueous medium with the enzyme at the appropriate pH and temperature for optimum enzyme activity. The product of the enzymic hydrolysis, after filtration through a bacterial filter, adjustment of the osmolality to an appropriate level of around 300 mOsm/Kg and the pH to physiological level of about 6.6 and addition of physiological salt levels, constitutes the final product.Type: GrantFiled: February 6, 1989Date of Patent: March 6, 1990Inventors: Thomas Gilchrist, William Manson
-
Patent number: 4902783Abstract: There is disclosed a method for purifying a gene-expression product produced by recombinant DNA technique which comprises a specific sequence of steps including adsorption treatment with silica gel, adsorption treatment with activated carbon, at least twice density gradient centrifugation and at least twice equilibrium density gradient centrifugation. The method of the present invention is very effective to remove allergen from gene-expression products contaminated therewith, enabling highly purified gene-expression products to be produced on a large scale.Type: GrantFiled: June 15, 1987Date of Patent: February 20, 1990Assignee: The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Hideo Goda, Toshiyuki Akiyama, Akihisa Takamizawa, Iwao Yoshida, Takeo Konobe, Keisuke Takaku
-
Patent number: 4895804Abstract: An isolated, substantially pure bovine pregnancy antigen for detecting and determining pregnancy in cattle consisting of a glycoprotein obtained from a pregnant bovine animal which is characterized by having a specific immunological reaction with a monoclonal antibody directed specifically against said glycoprotein wherein said monoclonal antibody is produced from hybridoma ATCC HB 8846.Type: GrantFiled: August 24, 1987Date of Patent: January 23, 1990Assignee: University of MinnesotaInventors: Eileen F. Bostwick, Alan G. Hunter
-
Patent number: 4888416Abstract: A method for preparing a dried protein product, such that the bioactivity and potential for solubility of the protein are substantially maintained when said product is administered to a living being and contacted with body fluids of said being, which comprises:(a) forming an aqueous solution comprising a mixture of said protein and an ionic detergent and(b) drying said protein-detergent mixture, wherein a sufficient amount of detergent is mixed with said protein in step (a) to substantially fully coat said protein.Type: GrantFiled: March 30, 1987Date of Patent: December 19, 1989Assignee: International Minerals & Chemical Corp.Inventors: Alvin M. Janski, Susan M. Drengler
-
Patent number: 4880512Abstract: A novel irradiation process and products made thereby. The process treats biological media such as blood fractions, genetically engineered protein products and vaccine preparations. The process photolyzes nucleic acids in preference to proteins in the media, e.g., it inactivates DNA- or RNA-containing pathogens while leaving the proteins substantially intact or functional. In general, the process comprises irradiating the medium with pulsed light of wavelength and flux selected so that (1) the nucleic acids in their ground state absorb radiation and thereby rise to an excited state or states, (2) the nucleic acids in their excited states absorb radiation and thereby rise to higher energy states and undergo photolysis, and (3) the proteins in their ground or their excited states do not absorb sufficient radiation to undergo substantial photolysis.Type: GrantFiled: October 14, 1988Date of Patent: November 14, 1989Assignee: Kollmorgen CorporationInventors: Paul A. Cornelius, Robin M. Hochstrasser, Neville R. Kallenbach, Harvey Rubin, George J. Todaro
-
Patent number: 4849510Abstract: A process for producing a cancer cell-derived glycosidic related antigen having a terminal fucose glycosidic linkage structure (TCA) and a process for producing a thermally denatured TCA are provided. These TCA and thermally denatured TCA have a very high immunogenicity that cause an immune response specific to cancer cells, and exhibit an excellent effect in the treatment and prevention of cancers.Type: GrantFiled: April 4, 1985Date of Patent: July 18, 1989Assignee: Otsuka Pharmaceutical Co., Ltd.Inventor: Masakazu Adachi
-
Patent number: 4849508Abstract: Pasteurization of immunoglobulin solutions to inactivate viruses without significantly altering the IgG molecules or their physiological activities is obtained with minimal aggregation in the absence of any stabilizer by heating this solution to mildly-elevated temperatures at low ionic strength and mildly acid pH values.Type: GrantFiled: November 24, 1987Date of Patent: July 18, 1989Assignee: Connaught Laboratories LimitedInventors: Anthony A. Magnin, Po-Shing Wah, Paul Dennis
-
Patent number: 4831120Abstract: An improved vector upon introduction into a suitable bacterial host containing the thermolabile repressor C.sub.I renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of a desired gene inserted into the vector and production of polypeptide encoded by the gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: a DNA sequence which contains the promoter and operator P.sub.L O.sub.Type: GrantFiled: July 3, 1985Date of Patent: May 16, 1989Assignee: Bio-Technology General Corp.Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel, Elisha Zeelon, Menachem Zeevi
-
Patent number: 4803073Abstract: The invention relates to a process for the pasteurization of plasma proteins and plasma protein fractions without essentially impairing their biological activity, by subjecting a suspension of the plasma proteins or plasma protein fractions in glycerol esters of saturated or singly or multiply unsaturated fatty acids having 4-22 carbon atoms, or mixtures of these esters, as the inert heat-transfer agent, with a maximum water content of the suspension of 1% by weight, to a heat treatment at temperatures of 50.degree. to 120.degree. C.Type: GrantFiled: March 9, 1987Date of Patent: February 7, 1989Assignee: Schwab & Co Ges.m.b.H.Inventors: Walter Doleschel, Walter N. Doleschel, Helmut Kaltschmid
-
Patent number: 4788056Abstract: Vaccines containing both E.coli and herpes virus were found not to provide adequate protection against subsequent herpes virus infections. The present invention is concerned with a E.coli herpes virus combined vaccine which provides protection against both types of pathogen.Type: GrantFiled: April 9, 1987Date of Patent: November 29, 1988Assignee: Akzo N.V.Inventors: Heinrich D. Lutticken, Nicolaas Visser, Eric O. Rijke
-
Patent number: 4774958Abstract: An ultrasonic imaging agent is formed by subjecting an aqueous protein solution to high frequency sonication while heating the solution sufficiently to denature portions of the protein, thereby forming a dispersion of microbubbles stabilized by denatured protein. In a preferred embodiment, the protein solution is formed from human serum albumin, and the formed microbubbles have a relatively uniform size in the 2 to 5 micron range, suitable for imaging of pulmonary or small organ vasculature.Type: GrantFiled: October 1, 1987Date of Patent: October 4, 1988Inventor: Steven B. Feinstein
-
Patent number: 4774323Abstract: A method of preparing von Willebrand Factor by disassociating it from a chaotropic agent in solution therewith and preferably treating the same under controlled temperature either in liquid or lyophilized form.Type: GrantFiled: June 29, 1987Date of Patent: September 27, 1988Assignee: Rorer Pharmaceutical CorporationInventors: Jack Newman, David L. Farb
-
Patent number: 4755460Abstract: A bovine pregnancy antigen, determined to be a glycoprotein, has been isolated and purified. If is diagnostic for the presence of pregnancy in cattle when detected by the use of antibodies to the antigen.Type: GrantFiled: July 6, 1984Date of Patent: July 5, 1988Assignee: The Regents of the Univ. of MinnesotaInventors: Eileen F. Bostwick, Alan G. Hunter
-
Patent number: 4749783Abstract: Preparation of active therapeutic proteins comprising two essential steps. In the first step an active protein source is treated under conditions sufficient to inactivate any viruses present (e.g. via heat or chemical treatment). In the second step, the treated active protein source of moderate purity is then treated under conditions sufficient to remove impurities as well as denatured (once active) proteins resulting from the viral inactivation step. In an illustrative embodiment, a biologically active protein such as antithrombin is treated under conditions sufficient to assure viral inactivation and minimal antithrombin deactivation. After the viral inactivation, the antithrombin is contacted with immobilized heparin to complex only the active antithrombin which is then eluted by known means and processed further (e.g., to include desired excipients and then freeze dried).Type: GrantFiled: July 11, 1986Date of Patent: June 7, 1988Assignee: Miles Laboratories, Inc.Inventors: Robert E. Jordan, Jaleh Kilpatrick
-
Patent number: 4743583Abstract: Lewis acid-Lewis base high molecular weight salt microparticulate material of the type referred to in U.S. Pat. No. 3,959,457, which include biologically active peptides and proteins solubilized in a non-aqueous, non-denaturing manufacturing solvent.Type: GrantFiled: July 20, 1987Date of Patent: May 10, 1988Assignee: Temple UniversityInventors: Tully J. Speaker, Tycho J. Speaker
-
Patent number: 4721777Abstract: Virus-contaminated immunoglobulin can be virus-inactivated by heating it in a substantially dry state at a temperature of 30.degree. to 100.degree. C. for a period of time sufficient for inactivating virus with maintaining original activity of the immunoglobulin. The addition of glycine, sodium chloride, sodium acetate, polyethylene glycol, albumin or mannitol enhances the effect and gives good solubility and good state to the solution of the virus-inactivated immunoglobulin.Type: GrantFiled: September 23, 1985Date of Patent: January 26, 1988Assignee: The Green Cross CorporationInventors: Yahiro Uemura, Katuhiro Uriyu, Tsuyoshi Takahashi, Takashi Goto, Masahiro Funayama, Masayuki Nishida, Tadakazu Suyama
-
Patent number: 4718433Abstract: A method of ultrasonic imaging for use in medical procedures is disclosed. The method comprises providing specifically defined microbubbles formed by sonicating a bicompatible liquid comprising a sonicated aqueous protein solution, preferably a 5% solution of human serum albumin, and denaturing the protein therein by heat or chemical methods; injecting the microbubbles into an animal or human to thereby alter the acoustic properties of an area to be imaged; and then ultrasonically scanning the area so as to obtain an ultrasound scanning image.Type: GrantFiled: December 5, 1985Date of Patent: January 12, 1988Inventor: Steven B. Feinstein
-
Patent number: 4695454Abstract: There is disclosed a process for producing a proteinaceous mass containing particles of HBsAg in a morphological form not found in nature while inactivating any live virus contained therein. The process comprises subjecting a concentrated mass thereof free of protein diluent or a stabilizer to a heat inactivation by heating the same while in a concentration of at least 1 mg/ml at a temperature of 101.degree. to 105.degree. C. for 1 to 5 minutes and thereafter cooling the so heated particles.Type: GrantFiled: April 1, 1985Date of Patent: September 22, 1987Assignees: New York Blood Center, Inc., Eugene Tech International, Inc.Inventors: Alfred M. Prince, Kwang S. Kim
-
Patent number: 4668584Abstract: A method is provided for forming ordered macromolecular protein arrays by avoiding a binding pathway that leads to densely packed, disordered states during protein crystal growth, by a diffusion limited process or by allowing controlled growth to occur by removal of the initial supported protein layer to a different environment.Type: GrantFiled: December 23, 1985Date of Patent: May 26, 1987Assignee: General Electric CompanyInventors: Egidijus E. Uzgiris, James R. Yates
-
Patent number: 4605444Abstract: In a process for preparing caseinates comprising the introduction of a mixture of casein, lyes and/or basic salts and water into a baking extruding device, in order to achieve a uniform product flow discharge and an end product with good water solubility, following on from a product feed zone of the baking extruding device, the mixture is supplied to a plasticizing zone with return elements and accompanied by pressure and temperature increases, and then to a discharge zone, it being expanded after discharge from the nozzle.Type: GrantFiled: October 24, 1984Date of Patent: August 12, 1986Assignee: Werner & PfleidererInventors: Werner Wiedmann, Christian Millauer